Copy
Having trouble viewing this message? View this email in a browser.
Share Share
Share Share
Forward Forward

AAFA Advocacy Drives Policy Change

AAFA's Asthma Capitals™ report not only highlights the factors that make living with asthma more challenging, but also helps drive an agenda that leads to policy change. 

On issues such as air pollution, access to medicine, and health equity, you've helped AAFA make a difference. 

Air Pollution
Poor air quality can negatively affect everyone’s health. Research shows that air pollution can make asthma worse and trigger asthma symptoms.

AAFA’s long-term advocacy for regulations to reduce carbon emissions got results this year in the form of new Environmental Protection Agency (EPA) rules on vehicle emissions that go into effect for the 2027 model year. 

These new rules will mean cleaner, healthier air and reduced exposure to a common asthma trigger. 

Access to Medicine
In previous research conducted by AAFA, people cited the cost of asthma medicines and the lack of health insurance coverage as reasons for not taking prescribed treatments.

This year, in part as a result of AAFA’s work with the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, several major manufacturers announced $35-a-month price caps on their asthma inhalers.

Health Equity
The Asthma Capitals report acknowledges that where a person lives can significantly impact their health. Social, economic, and environmental disadvantages play a role in determining asthma outcomes. Many of the top Asthma Capitals face major challenges and inequities that lead to health inequity.

Through AAFA's Health Equity, Advancement, and Leadership (HEAL) program, we are supporting the Allentown community (this year's #1 Asthma Capital) with developing and launching the EASE Allentown: Empowering Asthma Self-Management and Education program.

The goal is to develop a community-based asthma management program and outreach campaign focused on older adults with asthma.

Read our Asthma Capitals report to learn more about ways to bring about positive policy change for people with asthma.

    

Your donation helps support our work to improve health outcomes for people with asthma and allergies. 

 

DONATE

Asthma Medicine and Your Mental Health

While many people are aware of the physical impacts of asthma, mental health may also be impacted by this chronic condition.  

Sometimes, the medicines you take to treat your asthma affect your mental health.  

Our blog includes more information on asthma and your mental health and a note about the side effects of some medicines, including this important one: 

Serious mental health problems have happened in people who take Montelukast (brand name SINGULAIR®). Montelukast has a black box warning. This is a safety warning from the FDA. This means you need to be aware of a medicine’s side effects or important instructions for safe use of the medicine. We encourage you to speak with your health care provider before, during, and after the start of any new medicine. If your doctor recommends montelukast, talk with them about possible risks and concerns. 

RESEARCH NEWS

Our October 2024 research update includes summaries on current clinical trials, surveys, and study outcomes on the following topics: 

Anaphylaxis 

  • neffy® Epinephrine Nasal Spray Now Available in the U.S. 

Allergy 

  • How Climate Change Impacts Allergies 

  • Safety of Direct Penicillin Challenges 

Asthma 

  • Risk Factors for Missing Appointments Among Children with Asthma 

  • A Look at Azithromycin as a Low-Cost Asthma Treatment 

Eczema 

  • FDA Approves EBGLYSS™ for People 12 Years and Older with Moderate-to-Severe Atopic Dermatitis 

Chronic Spontaneous Urticaria (CSU) 

  • Dupixent® Phase 3 Trial Shows Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) 

Chronic Obstructive Pulmonary Disease (COPD) 

  • FDA Approves Dupixent as the First-Ever Biologic Medicine for Patients with COPD in the U.S. 

Eosinophilic Granulomatosis with Polyangiitis (EGPA) 

  • FDA Approves FASENRA for Eosinophilic Granulomatosis with Polyangiitis (EGPA) in the U.S. 

Nasal Polyps 

  • FDA Approves Dupixent® as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the U.S. 

To learn more about this month’s asthma and allergy news, visit our blog. 

CLINICAL TRIALS

Participate in Research for Potential Asthma Treatments

Individuals living with asthma have hope. A clinical trial is seeking volunteers who have experienced an asthma flare-up in the past year despite taking a daily management medication. Compensation may be available for eligible individuals. 
 
Sponsored by Antidote
LEARN MORE

SURVEYS

Community Asthma Survey

If you are over 18 and have asthma, we want to hear about how the environment affects your breathing. By telling your story, you can help others understand and manage asthma better! 

The Asthma and Allergy Foundation of America (AAFA) has a participating member on the survey steering committee and appreciates your support! 

                                                     

TAKE THE SURVEY



Participants Needed for Eczema Study

If you are a caregiver for a child under 18 with moderate to severe eczema, we would love to hear your opinions and perspectives. Your feedback can help impact guidelines for childhood eczema. Your child can take the survey too with your help. 

Take a 15-minute online survey for a research study on using systemic (oral or injectable) medicines for eczema. 

Your voice makes a difference! Each participant will be entered into a drawing for a reward.  

Principal Investigator: Dr. Joy Wan (Johns Hopkins Medicine IRB00397225) 

TAKE THE SURVEY

WEBINARS

People with respiratory diseases, such as asthma, have a greater chance of having nasal polyps. If you treat someone with nasal polyps, don’t miss these continuing medical education (CME) programs (and earn AMA PRA Category Credit™!): 

Did You Miss Our Previous Issue?

Check out our most recent issue for news and information on respiratory illnesses and eczema.

                               READ THE PREVIOUS ISSUE 

Thank you for your continued support.
Visit aafa.org and kidswithfoodallergies.org.

FOLLOW US:
Facebook Facebook
Instagram Instagram
YouTube YouTube
LinkedIn LinkedIn
Disclaimer: This newsletter is provided to you as a member and subscriber benefit and your use of it is in accordance with our website's terms of service.

Asthma and Allergy Foundation of America makes no representation, whatsoever, for the contents that may be contained in any of the sponsors or advertisers in this newsletter or the quality of any products, information, or other materials displayed, purchased or obtained by you as a result of an offer in connection with any advertisement. 

Please follow the instructions at the bottom of the newsletter to unsubscribe if you no longer wish to be on our newsletter mailing list. This newsletter is sent to all newsletter subscribers, registered members and donors of Asthma and Allergy Foundation of America.

Copyright © 2024 Asthma and Allergy Foundation of America, All rights reserved. ISSN 1939-8166.